



CHART NOTE EXAMPLE FOR INSERTION AND REMOVAL

Informed consent obtained after discussing procedure and possible complications. Allergies documented regarding procedural products.

Insertion:

Confirmed correct sensor type: **Eversense 365**. Confirmed correct sensor serial number for patient (if applicable) _____ and use-by date _____. Insertion area located in right/left upper arm and marked. Skin prepped with chlorahexadine/betadine x3, draped, and local anesthesia injected using 2 mL 1%/2% lidocaine with/without epinephrine. Incision made and sensor deployed.

Pressure applied to incision site, closed with Steri-strips or another method, and dressed. Patient tolerated procedure well without complications. Incision care instructions reviewed. Patient instructed to call if signs/symptoms of infection develop.

Sensor linked to transmitter and warm-up phase initiated. Signal strength documented as excellent/good/low.

Instructions were given for activating the system and the patient was given training materials on system usage.

Removal:

Previous sensor located by palpation and marked. Skin prepped with chlorahexadine/betadine x3, draped, and local anesthesia injected using 2 mL 1%/2% lidocaine with/without epinephrine.

Incision made. Sensor located and removed successfully.

Pressure applied to incision site, closed with Steri-strips or another method, and dressed. Patient tolerated procedure well without complications. Incision care instructions reviewed. Patient instructed to call if signs/symptoms of infection develop.

This document is intended for trained providers as an example of common chart notes used to document events of the Eversense CGM Insertion and/ or Removal procedure. It is not intended to be used as-is and should be amended to reflect each individual procedure and to meet individual standards of practice.



© 2026 Senseonics, Incorporated.
All rights reserved.

Manufactured by Senseonics, Inc.
20451 Seneca Meadows Parkway
Germantown, MD 20876-7005 USA
eversensecg.com

The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.

For safety information, see bit.ly/eversensesafety

Eversense, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective holders and are used solely for informative purposes. No relationship or endorsement should be inferred or implied. CLN-0106 Rev 1